SAB Biotherapeutics
SABS· Manufacturing· Fiscal year ends in December
CEO pay in FY2025Stock -1.4% in FY2025
Samuel J. Reich is the CEO of SAB Biotherapeutics and was paid $9.4M in FY2025 (Dec), up 265%.
Pay$100 in the stock at the end of FY21 → $5
Executives5
See all- 1Samuel J. ReichChief Executive OfficerFY2025
- 2Eddie J. Sullivan, PhD.PresidentFY2025
- 3Alexandra Kropotova, MDEVP, Chief Medical OfficerFY2025
- 4Christoph Bausch, PhDEVP, Chief Operating OfficerFY2025
- 5Lucy ToEVP, Chief Financial OfficerFY2023
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allSAB Biotherapeutics paid its 4 named executives $22.4M in total in FY2025 (Dec). CEO Samuel J. Reich was paid $9.4M of that.
| Name | |||
|---|---|---|---|
| Samuel J. ReichChief Executive Officer | |||
| Eddie J. Sullivan, PhD.President | |||
| Alexandra Kropotova, MDEVP, Chief Medical Officer | |||
| Christoph Bausch, PhDEVP, Chief Operating Officer | |||
| Lucy ToEVP, Chief Financial Officer | Not disclosed | Not disclosed |
of each named executive, from the Summary Compensation Table of each proxy.
Peers
No disclosed peer group
No proxy on file names a pay peer group for SAB Biotherapeutics. The peer group comes from the proxy statement, so it shows here when a proxy read has it.
Board2
See all- Jeffrey G. SpragensDirector · 4 yr on the boardIndependentAudit—Paid as an executive
- Andrew MoinDirector · 1 yr on the boardIndependentNominating—Paid as an executive
The board of the latest proxy (FY2024).
Activity
Filings6
See all| Proxy statement | DEF 14A | Apr 30, 2026 | FY2025 |
| Annual report | 10-K | Mar 9, 2026 | FY2025 |
| Proxy statement | DEF 14A | Jun 2, 2025 | FY2024 |
| Annual report | 10-K | Mar 31, 2025 | FY2024 |
| Proxy statement | DEF 14A | May 30, 2024 | FY2023 |
| Annual report | 10-K | Mar 29, 2024 | FY2023 |
